This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen project...
As Moderna maps out a more cautious future amid lower-than-expected sales of its...
The CDC Foundation has added muscle to its “Live to the Beat” campaign, enlistin...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma...
The company is in talks with individual regulatory authorities after its decisio...
With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 20...
With a $2.2 billion settlement, GSK has resolved most of its Zantac litigation. ...
Egypt's EVA Pharma, France’s DNA Script and Belgium’s Quantoom Biosciences on We...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA app...
As AstraZeneca faces an ongoing investigation into alleged illegal importation o...
Just nine months after announcing a massive plan to cut costs, Bristol Myers Squ...
Invivyd has teamed up with professional football coach Jim Harbaugh to tackle CO...
Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli...
Merck & Co. and AstraZeneca suffered notable losses in China during the fourth q...
In a lawsuit that received little attention toward the end of last year, Regener...
Last year marked the first time in Pfizer’s 175-year history that the drugmaker ...
Roche has detailed results of a phase 3 trial of its blood cancer drug Gazyva in...
Johnson & Johnson's proposed $14.6 billion purchase of Intra-Cellular Therapies ...
This week on "The Top Line," we dig into the 10 biggest potential drug launches ...
Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing att...
Bain Capital is laying out 510 billion Japanese yen ($3.3 billion) to acquire Mi...